Back to News
Market Impact: 0.15
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
Telix and Profound announced a collaboration to educate physicians and prostate cancer centers about the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO. The article provides no financial terms or quantified commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
PRN0.30
TLX0.30
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- What's behind the recovery rally in tech stocks — plus, Elon Musk's very good week
- Elon Musk intensifies attack on Ambani over Starlink India launch delay
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- Why is T-Mobile stock tumbling today?